selpercatinib
Eli Lilly Nabs Full FDA Approval for Retevmo in RET Fusion-Positive Thyroid Cancer
In converting a 2020 accelerated approval to a full approval, the agency lowered the RET inhibitor's age restriction from 12 years old to 2 years old.
FDA Lowers Pediatric Age for Eli Lilly's Retevmo
The RET inhibitor can now be given to children with RET-altered cancers as young as 2 years old.
Chugai Gains Japanese Approval for CDx for Eli Lilly's Retevmo
Roche's FoundationOne CDx cancer genomic profiling test was approved for the RET receptor tyrosine kinase inhibitor for RET fusion-positive solid tumors.
Eli Lilly to Share With Regulators Data on Retevmo Besting Standard Drugs in Thyroid Cancer Patients
The Phase III study data showing Retevmo improved progression-free survival in patients with RET-mutant tumors may support conversion from accelerated to full approval.
Eli Lilly to Discuss Positive Head-to-Head Retevmo Data in RET-Positive NSCLC With Regulators
Retevmo improved progression-free survival compared to chemo with or without Keytruda in the Phase III trial.